SeraCare Life Sciences launches new product to diagnose HIV

SeraCare Life Sciences, Inc. (NASDAQ: SRLS) today announced that the Company has launched a set of new products in its diagnostic controls and panels portfolio—the SeraCare HIV-1 Seroconversion Panels. Each of the six panels consists of a set of undiluted plasma samples from a single plasma donor collected over a period of time during the development of detectable specific antibodies to HIV in the blood, or seroconversion, and is highly characterized with enhanced product information. Extensively defined natural patient samples are vital for assay development and regulatory compliance. SeraCare's HIV seroconversion panels can be used by customers to accelerate development of new test methods, provide a common reference for assay comparison and troubleshoot existing assays.

“These latest new product offerings build on more than 20 years of SeraCare leadership in helping scientists develop diagnostic tools for HIV and support our continued future growth.”

"SeraCare's HIV product portfolio provides scientists with one of the industry's most comprehensive historical reference platforms to study this rapidly changing disease," said Susan Vogt, President and Chief Executive Officer. "These latest new product offerings build on more than 20 years of SeraCare leadership in helping scientists develop diagnostic tools for HIV and support our continued future growth."

SeraCare HIV-1 Seroconversion Panels are supplied with comprehensive test data vital for assay development and regulatory compliance, including results from twenty U.S. and international test methods for markers of HIV infection such as HIV RNA, 1st to 4th generation screening tests for HIV, confirmatory tests and a rapid discriminatory method. A seroconversion graph of critical data points is also included. The data for SeraCare's new HIV-1 Seroconversion Panels will be available at www.seracarepanels.com. The enhanced on-line data feature allows SeraCare to provide timely updates whenever new test data are available.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New HIV prevention injection offers 96% protection